Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Amortizatization of Intangibles: 2021-2025

Historic Amortizatization of Intangibles for Ascendis Pharma A (ASND) over the last 5 years, with Sep 2025 value amounting to $143,794.

  • Ascendis Pharma A's Amortizatization of Intangibles rose 13.86% to $143,794 in Q3 2025 from the same period last year, while for Sep 2025 it was $530,834, marking a year-over-year decrease of 1.65%. This contributed to the annual value of $505,452 for FY2024, which is 2.74% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Amortizatization of Intangibles of $143,794 as of Q3 2025, which was up 6.75% from $134,703 recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Amortizatization of Intangibles high stood at $161,391 for Q4 2023, and its period low was $111,918 during Q3 2022.
  • In the last 3 years, Ascendis Pharma A's Amortizatization of Intangibles had a median value of $126,295 in 2024 and averaged $130,127.
  • Per our database at Business Quant, Ascendis Pharma A's Amortizatization of Intangibles soared by 42.51% in 2023 and then decreased by 21.21% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Amortizatization of Intangibles (Quarterly) stood at $128,125 in 2021, then declined by 11.61% to $113,247 in 2022, then skyrocketed by 42.51% to $161,391 in 2023, then decreased by 21.21% to $127,163 in 2024, then climbed by 13.86% to $143,794 in 2025.
  • Its last three reported values are $143,794 in Q3 2025, $134,703 for Q2 2025, and $125,174 during Q1 2025.